J
John Cochran
As a 50 year old male with a bicuspid aortic valve, I've known for several
years that my valve would eventually need replacing. Up until this year, I
was pretty sure the Ross Procedure would be my choice. However, a new
option, not yet widely available, has changed my mind.
On April 24, I will be having my aortic valve replaced with a Cryolife
Synergraft aortic homograft (human valve). The Synergraft process
decellularizes the donor valve, leaving behind a functional collagen matrix.
This valve is not attacked by the immune system like a conventional
homograft, and in about one year my own cells should have repopulated the
valve, at which point it becomes my own living tissue. It is believed that
calcification will be dramatically reduced, or even eliminated.
Unfortunately, there are no 20-year studies on this technology since it is
so new. The Synergraft pulmonary valves (human) have been being used for
some Ross procedures, but it is only recently that the thicker aortic valve
(and therefore harder to process) has become available on a very small scale
through a couple of centers in the United States.
While there is great promise with this "tissue engineered" valve, e.g., long
and perhaps permanent solution, no blood thinners needed, etc., there are
also some risks. First, the valve may end up not repopulating, in which case
the life of the valve would be reduced. Second, the Synergraft process has
not been proven over a long period, so other unknown risks may exist. I
picked this option over the Ross to avoid the potential of having a
two-valve problem and because it reduces the amount of surgical trauma to my
heart. Psychologically, it is pleasing to think of this implanted valve
eventually becoming my own living tissue.
I am VERY anxious about the whole surgery experience, but this forum has
helped immensely by having a better idea of what to expect in general. I
will try to keep you all posted on my progress after surgery, and would be
happy to answer questions about this new valve.
You can email me at:
[email protected]
Best to you all,
John Cochran
years that my valve would eventually need replacing. Up until this year, I
was pretty sure the Ross Procedure would be my choice. However, a new
option, not yet widely available, has changed my mind.
On April 24, I will be having my aortic valve replaced with a Cryolife
Synergraft aortic homograft (human valve). The Synergraft process
decellularizes the donor valve, leaving behind a functional collagen matrix.
This valve is not attacked by the immune system like a conventional
homograft, and in about one year my own cells should have repopulated the
valve, at which point it becomes my own living tissue. It is believed that
calcification will be dramatically reduced, or even eliminated.
Unfortunately, there are no 20-year studies on this technology since it is
so new. The Synergraft pulmonary valves (human) have been being used for
some Ross procedures, but it is only recently that the thicker aortic valve
(and therefore harder to process) has become available on a very small scale
through a couple of centers in the United States.
While there is great promise with this "tissue engineered" valve, e.g., long
and perhaps permanent solution, no blood thinners needed, etc., there are
also some risks. First, the valve may end up not repopulating, in which case
the life of the valve would be reduced. Second, the Synergraft process has
not been proven over a long period, so other unknown risks may exist. I
picked this option over the Ross to avoid the potential of having a
two-valve problem and because it reduces the amount of surgical trauma to my
heart. Psychologically, it is pleasing to think of this implanted valve
eventually becoming my own living tissue.
I am VERY anxious about the whole surgery experience, but this forum has
helped immensely by having a better idea of what to expect in general. I
will try to keep you all posted on my progress after surgery, and would be
happy to answer questions about this new valve.
You can email me at:
[email protected]
Best to you all,
John Cochran